title-61-latestnews-en
 

U.S. MSKCC has published the results of the phase II clinical study of Maitake mushroom extract.

In October, 2014, Memorial Sloan-Kettering Cancer Center (MSKCC), U.S.A. published the results of the phase II clinical study of Maitake mushroom extract in Myelodysplastic syndromes (MDS) in Cancer Immunology, Immunotherapy Journal. The results demonstrated that Maitake mushroom has beneficial immunomodulatory effects in MDS patients.

Reference:

Wesa KM, Cunningham-Rundles S,Klimek VM et al.(2014) Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study. Cancer Immunol Immunother. DOI 10.1007/s00262-014-1628-6